GLOBOCAN

GLOBOCAN
Name	GLOBOCAN
Type	Database
Established	1990s
Maintained by	International Agency for Research on Cancer
Purpose	Global cancer incidence and mortality estimates

GLOBOCAN is a global project producing contemporary estimates of cancer incidence, mortality, and prevalence for most countries, intended as a resource for researchers, policymakers, and clinicians. The project is produced by the International Agency for Research on Cancer and interacts with national cancer registries, global health organizations, and academic institutions to inform planning, surveillance, and research priorities. Its outputs are used alongside data from national statistical offices, population surveys, and international agencies for comparative analyses and modeling.

Overview

GLOBOCAN provides modelled estimates of cancer burden by site, sex, and age for countries and territories, drawing on inputs from the International Agency for Research on Cancer, the World Health Organization, national cancer registries, and regional consortia such as the European Network of Cancer Registries, the African Cancer Registry Network, and the Latin American and Caribbean Network of Cancer Registries. The dataset is integrated into platforms maintained by organizations including the World Health Organization, the United Nations, the World Bank, and the Organisation for Economic Co-operation and Development, and is cited in reports by institutions such as the Centers for Disease Control and Prevention, the American Cancer Society, and the Lancet Oncology Commission. Users include ministries of health, academic centers like Johns Hopkins University, Harvard University, and the University of Oxford, and non-governmental organizations such as the Union for International Cancer Control and PATH.

Methodology and Data Sources

Estimates are derived from a combination of national population-based cancer registries, sample registry data, vital registration systems maintained by national statistical offices, and modeled inputs using tools and methods developed by the International Agency for Research on Cancer, the World Health Organization, and collaborators from universities such as Imperial College London and the University of Toronto. Inputs include anonymized registry datasets from networks like the European Network of Cancer Registries, the North American Association of Central Cancer Registries, and country programs supported by the Pan American Health Organization and the African Cancer Registry Network, supplemented by mortality data from national civil registration and vital statistics systems compiled by the United Nations Population Division and the World Health Organization. Analytical methods reference demography and epidemiology frameworks from institutions such as the United Nations Population Division, the Global Burden of Disease study led by the Institute for Health Metrics and Evaluation, and statistical approaches used by the International Classification of Diseases maintained by the World Health Organization, with modeling work contributed by groups at the London School of Hygiene & Tropical Medicine and the Karolinska Institutet.

Global and Regional Estimates

GLOBOCAN publishes point estimates of incidence, mortality, and prevalence for major cancer sites across global, regional, and national aggregates, with regional groupings that align with United Nations geoschemes and World Health Organization regions. Data are commonly reported for cancers such as lung, breast, colorectal, prostate, stomach, liver, cervical, and esophageal cancers, and regional patterns are compared across high-income settings like the United States, Canada, Japan, and Australia and lower-income settings in sub-Saharan Africa, South Asia, and Latin America. Publications and briefings often contrast GLOBOCAN outputs with findings from the Global Burden of Disease study, country cancer control plans from national ministries of health, and research articles from journals such as The Lancet, BMJ, and JAMA to highlight trends in incidence and mortality for populations in countries including China, India, Brazil, Russia, Nigeria, South Africa, and Egypt.

Uses and Applications

Researchers at universities and research centers including Johns Hopkins University, Harvard School of Public Health, and the University of Oxford use GLOBOCAN estimates in epidemiologic modeling, health economics analyses, and trend assessments alongside data from agencies like the World Health Organization, the World Bank, and the United Nations. Policymakers in ministries of health, national cancer control programs, and regional health bodies such as the Pan American Health Organization and the African Union reference GLOBOCAN for resource allocation, planning screening programs, and setting priorities for vaccination campaigns like HPV immunization endorsed by UNICEF and the Gavi Alliance. Non-governmental organizations including the Union for International Cancer Control and the American Cancer Society use estimates for advocacy, fundraising, and global awareness campaigns, while clinical guideline bodies such as the National Institute for Health and Care Excellence and the European Society for Medical Oncology consult population burden data when developing recommendations.

Limitations and Criticisms

Critics note that modeled estimates depend on the availability and quality of primary data from national cancer registries, vital registration systems, and sample surveys, with critiques voiced in literature from journals such as The Lancet, BMJ, and PLOS Medicine and by groups including the Global Burden of Disease collaborators. Limitations cited include under-ascertainment in registries from low-resource settings, misclassification issues tied to the International Classification of Diseases, temporal lags between data collection and publication, and uncertainties in model assumptions discussed by statisticians at Imperial College London, the Institute for Health Metrics and Evaluation, and the London School of Hygiene & Tropical Medicine. Debates continue among epidemiologists, demographers, and policy analysts from organizations like the World Health Organization, the United Nations, and national statistical offices about transparency, uncertainty quantification, and comparability with alternative estimates from the Global Burden of Disease study and national surveillance systems.

History and Development

Origins trace to efforts in the 1990s by the International Agency for Research on Cancer and collaborators to harmonize cancer incidence data across national registries, building on frameworks from the World Health Organization, the United Nations, and regional registry networks such as the European Network of Cancer Registries and the North American Association of Central Cancer Registries. Major updates have been released periodically to incorporate advances in demographic projections from the United Nations Population Division, improvements in cancer registration promoted by the International Agency for Research on Cancer and WHO, and methodological collaborations with academic partners at institutions including Harvard University, the University of Oxford, and Imperial College London. The project’s evolution has intersected with global health initiatives led by entities such as the World Health Assembly, the Gavi Alliance, and the Union for International Cancer Control, shaping its role in international cancer surveillance and public health planning.

Category:Cancer epidemiology